Fig. 6: HNRNPC expression is associated with clinical outcomes in patients with breast cancer.
From: An mRNA processing pathway suppresses metastasis by governing translational control from the nucleus
a, Kaplan–Meier survival curve showing association between tumour HNRNPC levels and disease-free survival in the METABRIC cohort. b, Kaplan–Meier survival curve showing association between tumour HNRNPC levels and overall survival in the TCGA-BRCA cohort. c, Kaplan–Meier survival curve showing association between tumour HNRNPC levels and distant metastasis-free survival (DMFS) in a collection of breast cancer patient cohorts. Hazard ratios (HR) and P values (calculated using log-rank test) are shown (a–c). d, HNRNPC mRNA levels across breast cancer tissue stages I–IV in the METABRIC cohort. P value calculated using one-way analysis of variance (ANOVA). Box centre reports the median value, the boundaries—the quartiles and the whiskers—and the 10th and 90th percentiles. e, HNRNPC mRNA levels in non-metastatic (M0) and metastatic (M1) breast tumours in the TCGA-BRCA cohort. P value calculated using two-tailed Mann–Whitney U test. Box plot characteristics as in d. f, Kaplan–Meier survival curve showing association between tumour PABPC4 levels and distant metastasis-free survival (DMFS) in a collection of breast cancer patient cohorts. Hazard ratios (HR) and P values (calculated using log-rank test) are shown. g, PABPC4 mRNA levels across breast cancer tissue stages I–IV in the METABRIC cohort. P value calculated using one-way ANOVA. Box plot characteristics as in d. h, Kaplan–Meier survival curve showing association between tumour PDLIM5 levels and distant metastasis-free survival (DMFS) in a collection of breast cancer patient cohorts. Hazard ratios (HR) and P values (calculated using log-rank test) are shown. i, MDA-LM2 cells treated with T4 or vehicle control (DMSO) at 3 µM for 6 h were injected via tail vein into NSG mice. Bioluminescence was measured at the indicated times (mean values are shown, error bars indicating standard error of the mean (s.e.m.); P value calculated using two-way ANOVA). Lung sections were stained with H&E (representative images shown). n = 4–5 mice per cohort. j, NSG mice were intravenously injected with MDA-LM2, and intraperitoneally injected with 10 mg kg−1 T4 or vehicle control for three consecutive days, starting on the day of cancer cell injection. Bioluminescence was measured at the indicated times (mean values are shown, error bars indicating s.e.m.; P value calculated using two-way ANOVA); area under the curve was measured at the final timepoint (P value calculated using one-tailed Mann–Whitney U test). n = 4–5 mice per cohort.
